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Abstract
Background: Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are a widely used class
of therapy in the treatment of chronic pain and inflammation. The drugs are effective and can be
relatively inexpensive thanks to available generic versions. Unfortunately the traditional NSAIDs
are associated with gastrointestinal complications in a small proportion of patients, requiring costly
co-therapy with gastro-protective agents. Recently, a new class of non-steroidal anti-inflammatory
agents known as coxibs has become available, fashioned to be safer than the traditional NSAIDs
but priced considerably higher than the traditional generics. To help physicians choose
appropriately and cost-effectively from the expanded number of anti-inflammatory therapies,
scientific bodies have issued clinical practice guidelines and third party payers have published
restricted reimbursement policies. The objective of this study is to determine whether an
educational intervention can prompt physicians to adjust their prescribing in accordance with these
expert recommendations.
Methods: This is an ongoing, randomized controlled trial. All primary care physicians in Manitoba,
Canada have been randomly assigned to a control group or an intervention study group. The
educational intervention being evaluated consists of an audit and feedback mechanism combined
with optional participation in a Continuing Medical Education interactive workshop. The primary
outcome of the study is the change, from pre-to post-intervention, in physicians' appropriate
prescribing of non-steroidal anti-inflammatory therapies for patients requiring chronic treatment.
Three classes of non-steroidal anti-inflammatory therapies have been identified: coxib therapy,
traditional NSAID monotherapy, and traditional NSAID therapy combined with gastro-protective
agents. Appropriate prescribing is defined based on international clinical practice guidelines and the
provincial drug reimbursement policy in Manitoba.
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Traditional non-steroidal anti-inflammatory drugs
(NSAIDs) are a widely prescribed class of therapy used to
relieve pain and inflammation. The drugs have been
shown to be effective for a variety of common disorders
(hence their widespread use), most notably chronic oste-
oarthritis and rheumatoid arthritis. They are relatively
inexpensive due to the available generic versions, but
unfortunately have clinically important drawbacks related
to their gastrointestinal (GI) toxicity [1]. Each year, about
1% to 1.5% of patients taking traditional NSAIDs experi-
ence serious GI side effects such as perforations, ulcers,
and bleeding [2-5]. When multiplied by the total number
of NSAID users this translates into significant patient mor-
bidity and mortality [1,6] and is associated with consider-
able health care costs related to hospitalizations or to the
prescribing of expensive gastro-protective agents (GPAs)
[7-12]. The cause of this GI toxicity is the "non-selective
nature" of traditional NSAIDs that block both cyclo-oxy-
genase-2 (Cox-2), an enzyme involved in the production
of inflammation and pain, and Cox-1, a related molecule
that functions in GI tract mucosal protection and platelet
function [13].
In the last five years, a new class of non-steroidal anti-
inflammatory agents has become available to physicians,
fashioned specifically to be safer than the traditional
NSAIDs but priced at least two to three times higher than
the generic versions of traditional NSAIDs [14]. The new
drugs preferentially inhibit Cox-2 enzymes as compared
to COX-1 molecules, and therefore have been christened
"Cox-2 selective inhibitors" or "coxibs" for short. Large
clinical trials comparing the use of coxibs to traditional
NSAIDs have lent support to the concept that the new
agents offer an improved GI safety profile while maintain-
ing comparable analgesic efficacy in patients with chronic
arthritis [3,4,15]. The trials, however, have also hinted
that the improved GI safety may be compromised by con-
comitant use of low-dose aspirin [4] and may come at the
expense of some cardiovascular safety, although these
data remain controversial [16,17]. Regardless, the intro-
duction of these new anti-inflammatory agents has
prompted the question: when is it appropriate and cost-
effective to prescribe coxibs versus traditional NSAID
monotherapy or traditional NSAIDs in combination with
GPAs?
To assist physicians in selecting from the different classes
of anti-inflammatory agents, various scientific bodies
have published clinical guidelines and third party payers
have issued restricted reimbursement criteria [18-24].
These guidelines and reimbursement criteria in general
propose that, for the treatment of chronic osteoarthritis
and rheumatoid arthritis, coxibs should be used in lieu of
traditional NSAID monotherapy when patients have an
elevated risk for serious GI events. Traditional NSAID
therapy in combination with certain GPAs (misoprostol
or proton pump inhibitors) is also recommended as an
alternative for most high-risk patients. High-risk patients
are identified as individuals who have one or more of the
following clinical characteristics: a history of peptic ulcer
disease; advanced age (over 65 years); concomitant use of
corticosteroids or anticoagulants; multiple comorbid con-
ditions; or use of high doses or multiple NSAIDs
[1,5,6,25,26]. These high-risk patients are considered to
benefit from the improved GI safety of coxibs or from the
GI protection afforded by GPAs. Furthermore, coxibs and
GPA co-therapy have been shown to be cost-effective in
such high-risk patients, as the increased cost of the drugs
is partially offset by significant reductions in morbidity
and mortality and related expenses [14,27-29].
With these guidelines and policies on prescribing in place,
it is now important for physicians to adjust their prescrib-
ing practices accordingly. This is true both for rheumatol-
ogy specialists and for physicians in the primary care
setting where osteoarthritis patients are frequently man-
aged. Unfortunately, experience and educational research
show that simply making guidelines available does not
elicit behavioural change from physicians [30-33]. In the
case of anti-inflammatory drug prescribing, there is
already evidence showing that despite the availability of
guidelines and reimbursement policies, physicians'
choices of drugs remain suboptimal both in terms of the
inappropriate use of traditional NSAIDs and the non-cost-
effective use of coxibs [34-38].
The current use of anti-inflammatory drugs suggests a
need for strategies that will prompt physicians to change
their prescribing practice in accordance with the expert
recommendations. Preferably, strategies should be inves-
tigated that have proved successful at altering physician
behaviour in other settings.
In this paper, we describe a randomized controlled study,
which we are presently conducting, to evaluate the impact
of an educational intervention on primary care physi-
cians' prescribing of non-steroidal anti-inflammatory
therapies. The study, being conducted in the province of
Manitoba, Canada, tests the hypothesis that this interven-
tion will significantly improve physician appropriate pre-
scribing of anti-inflammatory drugs in compliance with
international clinical practice guidelines and Manitoba's
restricted drug reimbursement policy [18-22]. The inter-
vention being tested is modelled on proven approaches to
changing physician behaviour; it consists of an audit and
feedback mechanism with optional participation in a
Continuing Medical Education (CME) interactive work-
shop. This manuscript summarizes Phases II to V of a
larger initiative entitled the Manitoba Appropriate Anti-Page 2 of 9
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began in November 2000 and is currently in the data anal-
ysis stage. In this paper, we relate in detail the protocol of
this randomized controlled study.
Methods
Study population
MAAUI is a province-wide population-based study. All
primary care physicians (non-specialists) registered with
the College of Physicians and Surgeons of Manitoba and
practicing in Manitoba since July 1995 were eligible to
enter MAAUI. The study excluded residents, new physi-
cian graduates, physicians registered as specialists, and
physicians who started practicing in the province of Mani-
toba after July 1995. The eligible study population thus
totalled approximately 884 physicians.
All eligible physicians were automatically entered into the
MAAUI protocol. Physicians who were randomized to
intervention group of the research were given the option
to withdraw from the study. Six family physicians who
agreed to act as facilitators for the MAAUI CME workshop
were not included in the study population.
Study design
The MAAUI study design is depicted in Figure 1. Primary
care physicians were allocated to the control and interven-
tion arms of the study using a stratified randomization
process. Specifically, study participants were divided into
groups according to the geographical area of their practice
within Manitoba. These groups were stratified by physi-
cians' "urban" (within Winnipeg – the provincial capital,
population size 676,700) or "rural" (outside of Winnipeg,
population size 468,300) practice location. Randomiza-
tion within each stratum was then carried out at the level
of the group. The MAAUI research team originally identi-
fied 12 urban and 11 rural areas in Manitoba based on
existing community boundaries within Winnipeg and the
presence of distinct regional health districts outside of
Winnipeg. Because one urban and rural area each con-
tained very few primary care physicians (less than five),
these areas were joined to neighbouring regions resulting
in 11 urban and 10 rural groups. Urban and rural groups
were randomized in such a way as to achieve a 1:2 ratio of
control to intervention groups. Four of the urban groups
and three of the rural groups were randomized to the con-
trol arm, and the remaining seven urban and seven rural
groups were randomized to the intervention arm.
This study design was chosen for several reasons. First, it
offered the scientific rigour that is associated with rand-
omization and the use of a control group. It also ensured
that both rural and urban Manitoban physician groups
had an equal opportunity to take part in and learn from
the study intervention. The study design was also particu-
larly amenable to testing an intervention that required
physicians to congregate in common locations (i.e. for the
CME workshop). The 1:2 ratio of study groups helped to
ensure that there were a sufficient number of study partic-
ipants who would consider attending the CME
workshops.
The educational intervention
Physicians allocated to the intervention arm of MAAUI
were mailed a package that included an introduction to
the study, audit and feedback material, and an invitation
to participate in a CME workshop. Physicians in the con-
trol arm received no package.
Audit and feedback material
The audit and feedback material consisted of a "Personal-
ised Prescribing Profile" (see Figure 2). This profile illus-
trated for each physician his/her recent prescribing pattern
of non-steroidal anti-inflammatory therapies and the
appropriateness of this prescribing pattern in light of
expert recommendations. Specifically, the profile con-
tained a bar chart showing the number of patients to
whom the physician had prescribed long-term treatment
with coxibs, traditional NSAID monotherapy, or tradi-
tional NSAIDs in combination with GPAs between August
1999 and September 2000. The proportion of these
patients with whom the prescription was appropriate was
also included. Long-term treatment was defined as
patients who received therapy for a minimum of 100 days
during this period. The chart, in addition to showing the
physician's own prescribing profile, also showed the aver-
age profile of primary care physicians in the same geo-
graphical area and the profile of Manitoban primary care
physicians overall. The reverse side of the chart listed the
criteria used to define appropriate prescribing. These crite-
ria were based on international clinical practice guidelines
and Manitoba's restricted drug reimbursement policy for
coxibs, and were verified by a rheumatologist on the
MAAUI research team [18-22]. The criteria identified cox-
ibs or traditional NSAID/GPA combination therapy as the
appropriate choice for patients at risk for serious GI com-
plications. The criteria also identified coxibs as the only
appropriate therapy for patients with bleeding disorders
or patients taking concomitant anticoagulants (this latter
recommendation was based in part on Manitoba's reim-
bursement policy for coxibs and in part on the Canadian
Consensus guidelines, and reflected concerns over the
anti-platelet effect of traditional NSAIDs [18,22]). The for-
mat of the Personalised Prescribing Profiles was devel-
oped by the MAAUI research team and was validated prior
to the study intervention using two focus groups of family
physicians.
The Personalized Prescribing Profiles were generated by
Manitoba Health and the Manitoba Centre for HealthPage 3 of 9
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MAAUI study design
November, 2000
4 urban groups and 3 rural groups 7 urban groups and 7 rural groups
in the Control Arm in the Intervention Arm
Mailed audit and feedback material
and invitation to CME workshop
August, 2001
Withdrawal of Withdrawal of
▪ workshop facilitators ▪ workshop facilitators
▪ physicians who opted 
  out of the study
Optional participation in a CME workshop 
Fall 2001
Withdrawal of
▪ physicians who opted 
  out of study
Primary outcome = the change in appropriate prescribing of anti-inflammatory therapies  
from pre-intervention (October 1, 2000 to July 31, 2001) to post-intervention
 (October 1, 2001 to March 31, 2002); measured for each individual physician
Stratified Randomization
Manitoba Primary Care Physicians 
11 urban groups and 10 rural groups 
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Generic example of a Personalised Prescribing Profile. The Personalised Prescribing Profile constituted the audit and 
feedback mechanism in MAAUI. Every physician in the intervention arm of the study was sent a Personalised Prescribing Profile 
by mail. a/ Side 1 of the profile provides a brief introduction to the purpose of the profile and lists the criteria for appropriate 
prescribing of coxibs, traditional NSAIDs (referred to as "NSAIDs" throughout the Profile), and traditional NSAID/GPA com-
bination therapy. b/ On side 2, a bar chart illustrates for the physician his/her recent prescribing pattern of chronic non-steroi-
dal anti-inflammatory therapies. The chart includes the number of patients to whom the physician has prescribed long-term 
treatment with each of the anti-inflammatory therapies between August 1999 and September 2000 and the proportion of these 
patients for whom the prescription was appropriate ("Recommended Treatment") or inappropriate ("Not a recommended 
treatment"). The chart also provides averaged statistics on appropriate and inappropriate prescribing for the physicians in the 
same geographical area and for primary care physicians in Manitoba overall.Page 5 of 9
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administrative data from the Population Health Research
Data Repository. This repository contains anonymized
encounter-based records of individuals' interactions with
the provincial health care system and is derived from
information received by the Department of Health, Prov-
ince of Manitoba, as part of the routine provision of
health care in the province. The repository includes Physi-
cian Registry files, Medical Claims and Hospital discharge
files, as well as Drug Programs Information Network
(DPIN) files. The DPIN contains records of all drugs dis-
pensed by Manitoba pharmacies, regardless of who is
responsible for payment.
Because of the sensitive nature of the Personalised Pre-
scribing Profiles, the individualized profiles were not seen
by the MAAUI research team. Instead the packages con-
taining the profiles were assembled and mailed out by
Manitoba Health with the assistance of an independent
researcher, hired by the MAAUI research team, who signed
a confidentiality agreement with Manitoba Health.
CME workshop
The CME workshop for MAAUI was entitled "The Utiliza-
tion and Prescribing of Anti-inflammatory Drugs in Oste-
oarthritis". The workshop focused specifically on the
prescribing for osteoarthritis, as it was felt that people
with this disease account for a large proportion of the
chronic non-steroidal anti-inflammatory use by primary
care practices [39].
Eleven CME workshops were held throughout Manitoba
(four within Winnipeg and seven outside of Winnipeg)
and physicians in the intervention group were invited to
voluntarily attend one of the 11. The workshops were free
of charge and were approved for 3.0 hours of MAINPRO-
M1 credits (continuing education credits awarded by the
College of Family Physicians of Canada for group learning
activities). Each workshop was facilitated by a trained
family physician.
The workshops included three components: an introduc-
tory video, a decision tree, and a case study portion. The
introductory video provided the history and rationale of
MAAUI, explained aspects of the Personalised Prescribing
Profile, and introduced the decision tree. The decision tree
depicted a stepwise approach to the diagnosis and treat-
ment of osteoarthritis. This aid was designed by a rheuma-
tologist on the MAAUI research team specifically for use in
the study and was based on international clinical practice
guidelines and Manitoba's drug reimbursement policy
[18-22]. A take-home copy of the decision tree was pro-
vided to each workshop participant (see Additional file
1). Finally, the case study portion of the workshop con-
sisted of studies exploring both the diagnosis and appro-
priate treatment of osteoarthritis. These case studies were
supplied from an existing CME curriculum entitled "Clin-
ical Scenarios in Osteoarthritis" [40].
The overall MAAUI educational intervention, including
both the audit and feedback material and the optional
CME interactive workshop, was chosen by the MAAUI
research team based on the success of similar interven-
tions in the past. Audit and feedback mechanisms have
shown moderate success in changing physician behaviour
in past studies [41]. Equally, the addition of a continuing
education workshop to an existing intervention has been
shown to increase the impact on physician behaviour
[42]. Workshops with interactive elements, such as case
studies, have also been found to be more successful at
influencing physician behaviour than purely didactic lec-
tures [43]. Affordability, practicality, and reproducibility
were also considered when designing the intervention.
Outcomes
Principal outcomes
The primary goal of MAAUI is to evaluate the impact of
the educational intervention on physician appropriate
prescribing of non-steroidal anti-inflammatory therapies
for patients requiring long-term treatment. To this end,
four principal outcome measures have been developed:
• the change in appropriate prescribing of all non-steroi-
dal anti-inflammatory therapy (including coxibs, tradi-
tional NSAIDs, and traditional NSAID/GPA combination
therapy) from pre-to post-intervention;
• the change in appropriate prescribing of coxibs from
pre-to post-intervention;
• the change in appropriate prescribing of traditional
NSAID/GPA combination therapy from pre-to post-inter-
vention; and
• the change in appropriate prescribing of traditional
NSAID monotherapy from pre-to post-intervention.
These primary outcomes will be evaluated at the level of
the individual physician and will be calculated using
administrative data similar to that used to create the Per-
sonalised Prescribing Profiles. The change in appropriate
prescribing (AP) for a given physician will be calculated
by the physician's rate of appropriate prescribing during a
6-month period post-intervention (October 1st 2001 to
March 31st 2002) minus this rate during a 10-month
period immediately pre-intervention (October 1st, 2000
to July 31st, 2001). The rate of appropriate prescribing will
be defined as the number of patients prescribed long-term
treatment in whom the treatment was appropriate,
divided by the total number of patients prescribed long-Page 6 of 9
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expressed:
Physician's ∆AP = Post-intervention AP - Pre-intervention
AP
Appropriateness of prescribing will be calculated by a
researcher who is blinded to participants' study-arm allo-
cation, and will be based on the same criteria as listed in
the Personalised Prescribing Profiles (see Figure 2a). In
the event that a physician has fewer than five patients on
long-term treatment in either the pre- or post-intervention
period, that physician's data will be withheld from analy-
sis to ensure confidentiality of the patients.
Secondary outcomes
In addition to the four principal outcomes, the MAAUI
study has a number of prospectively-defined secondary
outcomes:
• The study will re-evaluate the primary outcomes in the
following two physician subgroups: physicians who
received the audit and feedback material and attended the
CME workshop; physicians who received the audit and
feedback material and chose not to attend the CME work-
shop. This analysis will help to determine the impact that
the different components of the educational intervention
had on physician behaviour.
Specifically in the subgroup of physicians who attended
the CME workshop:
• The study will measure the change in physician knowl-
edge of osteoarthritis from pre-CME workshop to imme-
diately post-CME workshop and the change in knowledge
from pre-CME workshop to five months post-CME work-
shop. These two outcomes should provide insight into
physicians' retention of information following a CME
workshop and will allow us to examine any relationship
between change in physician knowledge and change in
physician prescribing behaviour.
• The study will also survey physicians' perceived change
in prescribing behaviour at five months post-intervention.
This outcome, compared with the principal study out-
comes, will provide insight into the accuracy with which
physicians' discern their own prescribing practices.
• The study will collect process-related measures in order
to mark areas for improvement in the study interventions.
Specifically, physicians' impressions of the Personalised
Prescribing Profile and CME workshop will be surveyed
using the questionnaire distributed immediately follow-
ing the CME workshop and using focus-group discussions
at the end of the study follow-up. All workshop partici-
pants will be invited to attend a follow-up focus group
(one for urban participants and one for rural partici-
pants). A separate focus group will be held for the work-
shop facilitators.
Baseline data collection
The following data were collected at baseline (October 1st,
2000 to July 31st, 2001) as control measurements: i) phy-
sician demographics including sex, urban or rural practice
location, and the number of years in practice; ii) physician
volume of non-steroidal anti-inflammatory therapies pre-
scribed annually for patients requiring chronic therapy;
and iii) physician rate of appropriate prescribing of
NSAIDs. These latter two measures were assessed for each
of coxibs, traditional NSAID/GPA combination therapy,
and traditional NSAID monotherapy.
Sample size and statistics
Sample size was calculated based on the need to detect at
least a 10% improvement in physician practice patterns
associated with the intervention, for clinical significance.
Alpha error was set at 1% because of the multiple primary
outcomes and power was set at 80%. It was also assumed
in the sample size calculation that physician baseline
demographic measures and baseline practice patterns
would contribute an additional 10% variation to the out-
comes. Based on these figures and using sample size tech-
niques for multivariate regression analysis [44], we
estimated the need for a minimum of 116 physicians in
the control group and intervention group respectively.
Multivariate regression analysis will be used to determine
if the study intervention has a significant impact on the
primary outcomes. Baseline data will be included as con-
trol measures and interaction effects between these base-
line data and the intervention will also be evaluated.
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Decision Tree: take-home copy
Decision Tree: take-home copyThe decision tree was a component of the 
MAAUI CME workshop. Physicians were introduced to the decision tree 
during the workshop and were provided with a two-sided take-home copy. 
The decision tree depicts a stepwise approach to the diagnosis and treat-
ment of osteoarthritis. a/ Side 1. b/ Side 2. Of note, on side 2 of the deci-
sion tree the term "NSAID" denotes traditional NSAIDs.
click here for file
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